Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Fennec Pharmaceuticals, retaining the price target of $13.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors tied to PEDMARK’s expanding clinical and commercial profile. He highlights the initiation of multiple investigator-sponsored studies in adolescent, young adult, and adult cancer patients, which he believes could broaden PEDMARK’s use beyond its current pediatric label and strengthen real-world evidence supporting its ability to reduce cisplatin-induced hearing loss.
He also points to the planned registration effort in Japan, where positive pivotal data exist but no revenue is yet modeled, leaving meaningful upside if approval and partnering are achieved. Based on a risk-adjusted net present value analysis, he estimates PEDMARK and pipeline assets support a firm value near $500M, implying a $13 per-share target despite acknowledged risks around new territory approvals, U.S. uptake, partnering, and future competition.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 20.7% and a 52.09% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, Rhythm Pharmaceuticals, and Emergent Biosolutions.